Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
h7HHVmdydagM9Fk4
